• LAST PRICE
    3.3650
  • TODAY'S CHANGE (%)
    Trending Up0.0250 (0.7485%)
  • Bid / Lots
    3.2000/ 1
  • Ask / Lots
    3.3900/ 3
  • Open / Previous Close
    3.3500 / 3.3400
  • Day Range
    Low 3.3400
    High 3.5900
  • 52 Week Range
    Low 1.7200
    High 3.8400
  • Volume
    36,661
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.34
TimeVolumeACST
09:32 ET27113.35
09:33 ET1003.425
09:35 ET3003.42
09:44 ET39533.58
09:50 ET11363.58
09:53 ET3933.5887
09:57 ET6053.48
10:20 ET8153.35
10:26 ET4003.35
10:27 ET18303.35
10:29 ET12543.35
11:25 ET4863.3401
11:39 ET1103.3487
12:42 ET1003.35
12:57 ET1543.35
01:15 ET4593.4
01:29 ET2963.3475
02:39 ET9823.3863
03:03 ET154673.35
03:15 ET13133.35
03:51 ET1003.39
03:55 ET4483.365
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACST
Acasti Pharma Inc
29.2M
-0.7x
---
United StatesLEXX
Lexaria Bioscience Corp
28.3M
-2.7x
---
United StatesCHHE
China Health Industries Holdings Inc
25.6M
-190.2x
---
United StatesVYNE
Vyne Therapeutics Inc
31.1M
-0.2x
---
United StatesETST
Earth Science Tech Inc
22.0M
106.5x
---
United StatesNDTP
NDT Pharmaceuticals Inc
20.0M
0.0x
---
As of 2024-02-22

Company Information

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Contact Information

Headquarters
3009 Boul. De La Concorde East, Suite 102LAVAL, QC, Canada H7E 2B5
Phone
450-686-4555
Fax
450-686-2505

Executives

Independent Chairman of the Board
Roderick Carter
Chief Executive Officer
Prashant Kohli
Principal Financial Officer, Principal Accounting Officer
Robert Delaversano
Vice President - Clinical Operations
Carrie D'Andrea
Vice President - Program Management
Amresh Kumar

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$29.2M
Revenue (TTM)
$0.00
Shares Outstanding
9.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.44
EPS
$-5.06
Book Value
$9.14
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.